<!doctype html>
<html class="no-js" lang="en">
  <head>
    <meta charset="utf-8">
		<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=0, minimum-scale=1.0, maximum-scale=1.0">
    <meta name="format-detection" content="telephone=no">
		<title>Dosing</title>
    <link rel="stylesheet" href="../shared/css/foundation.css" type="text/css">
    <link rel="stylesheet" href="../shared/css/global.css" type="text/css">
    <link rel="stylesheet" href="css/slide.css" type="text/css">
    <script type="text/javascript" src="../shared/js/vendor/modernizr.js"></script>
  </head>
  <body id="E05" class="subpage" data-trace="trace_e05-dosing_recos.jpg">
    <main class="slide">
      <div class="row collapse">
        <section class="columns">
          <nav id="header-nav" class="row"></nav>
          <article class="row landscape">
            <h2 class="left">Dosing</h2>
            <ul class="tabs" data-tab>
              <li class="tab-title active">
                <a href="#recos_tab" aria-selected="true">Dosing Recommendations</a>
              </li>
              <li class="tab-title">
                <a href="#consider_tab">Consider Aptiom</a>
              </li>
              <li class="tab-title">
                <a href="#tablets_tab">Aptiom Tablets</a>
              </li>
            </ul>
            <div class="tabs-content">
              <section class="content relative" id="consider_tab">
                <figure class="panel callout" data-bg>
                  <div>
                    <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>FINE-TUNED FOR DOSING FLEXIBILITY</h1>
                  </div>
                </figure>
                <h4>Consider APTIOM FOR YOUR PATIENTS' AED REGIMENS</h4>
                <figure class="chart relative">
                  <img alt="" src="img/chart-aed_regimens.svg">
                  <ul class="absolute" data-step-animated rel="aed_regimens">
                    <li class="transparent">
                      <img alt="" src="../shared/img/icon_check.svg" width="35">
                    </li>
                    <li class="transparent">
                      <img alt="" src="../shared/img/icon_check.svg" width="35">
                    </li>
                    <li class="transparent">
                      <img alt="" src="../shared/img/icon_check.svg" width="35">
                    </li>
                    <li class="transparent">
                      <img alt="" src="../shared/img/icon_check.svg" width="35">
                    </li>
                    <li class="transparent">
                      <img alt="" src="../shared/img/icon_check.svg" width="35">
                    </li>
                  </ul>
                  <figcaption>
                    <ul class="disc">
                      <li>APTIOM metabolites are eliminated from the systemic circulation primarily by renal excretion&sup1;</li>
                      <li>Some adverse reactions occur more frequently when patients take APTIOM adjunctively with carbamazepine. When APTIOM and carbamazepine are taken concomitantly, the dose of APTIOM or carbamazepine may need to be adjusted based on efficacy and tolerability. APTIOM should not be taken as an adjunctive therapy with oxcarbazepine. For patients taking other enzyme-inducing AEDs (i.e., phenobarbital, phenytoin, and primidone), higher doses of APTIOM may be needed&sup1;</li>
                      <li>A dose reduction is recommended in patients with moderate and severe renal impairment (i.e., creatinine clearance &lt;50&nbsp;mL/min).&sup1;</li>
                      <li>Dose adjustments are not required in patients with mild to moderate hepatic impairment. Use of APTIOM in patients with severe hepatic impairment has not been studied, and use in these patients is not recommended.&sup1;</li>
                      <li>Concomitant use of APTIOM and oral contraceptives containing ethinylestradiol and levonorgestrel is associated with lower plasma levels of these hormones. Patients should use additional or alternative non-hormonal birth control during APTIOM treatment and after discontinuation of APTIOM for one menstrual cycle, or until otherwise instructed.&sup1;</li>
                    </ul>
                  </figcaption>
                </figure>
                <aside data-isi-link></aside>
              </section>
              <section class="content active relative" id="recos_tab">
                <figure class="panel callout" data-bg>
                  <div>
                    <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>FINE-TUNED FOR DOSING FLEXIBILITY</h1>
                  </div>
                </figure> 
                <img src="img/logo-qd.svg" id="logo-qd" alt="" class="absolute">
                <h3>APTIOM flexible dosing is based on clinical response and tolerability&sup1;</h3>
                <h4>APTIOM DOSING RECOMMENDATIONS&sup1;</h4>
                <table>
                  <thead>
                    <tr>
                      <th>Initial Dose</th>
                      <th>Titration:<span class="weak block">Weekly increments*</span></th>
                      <th>Recommeded <br>maintenance dosage</th>
                    </tr>
                  </thead>
                  <tfoot>
                    <tr>
                      <td colspan="3">
                        <ul class="asterisk">
                          <li>Based on clinical response and tolerability.</li>
                        </ul>
                      </td>
                    </tr>
                  </tfoot>
                  <tbody>
                    <tr>
                      <td>400 mg QD</td>
                      <td>400 mg to 600 mg QD</td>
                      <td>800 mg to 1600 mg QD</td>
                    </tr>
                  </tbody>
                </table>
                <ul class="disc">
                  <li>Treatment may be initiated at 800 mg QD if the need for seizure reduction outweighs an increased risk of <br>adverse reactions during initiation</li>
                  <li>For patients on APTIOM monotherapy, the 800-mg QD maintenance dose should generally be considered in <br>patients who are unable to tolerate a 1200-mg daily dose</li>
                  <li>For patients on APTIOM adjunctive therapy, the 1600-mg daily dose should generally be considered in patients <br>who did not achieve a satisfactory response with a 1200-mg daily dose</li>
                  <li>In patients with moderate and severe renal impairment (i.e., creatinine clearance &lt;50 mL/min), dosages should <br>generally be reduced by 50% 
                    <ul>
                      <li>Initiate at 200 mg QD, increase by 200 mg to 300 mg QD weekly; 400-mg to 800-mg QD recommended maintenance&nbsp;dosage</li>
                      <li>Titration and maintenance dosages may be adjusted according to clinical response</li>
                    </ul>
                  </li>
                  <li>APTIOM is available in 200-mg, 400-mg, 600-mg, and 800-mg tablets</li>
                </ul>
                <aside data-isi-link></aside>
              </section>
              <section class="content relative" id="tablets_tab">
                <figure class="panel callout" data-bg>
                  <div>
                    <h1><small>For the treatment of partial-onset seizures as monotherapy or adjunctive therapy</small>FINE-TUNED FOR DOSING FLEXIBILITY</h1>
                  </div>
                </figure>
                <img src="img/logo-qd.svg" id="logo-qd-too" alt="" class="absolute">
                <h4>Aptiom is available in 200-<span class="lowercase">mg</span>, 400-<span class="lowercase">mg</span>, 600-<span class="lowercase">mg</span>, and 800-<span class="lowercase">mg</span> tablets&sup1;</h4>
                <figure class="chart relative">
                  <img alt="" src="img/chart-tablets.svg">
                  <figcaption>
                    <p>Tablets shown are actual size.</p>
                    <ul class="disc">
                      <li>Tablets may be taken either whole or crushed, with or without food&sup1;</li>
                    </ul>
                  </figcaption>
                </figure>
                <aside data-isi-link></aside>
              </section>
            </div>
          </article>
          <article class="row portrait"></article>
        </section>
        <aside id="sidebar" class="columns"></aside>
      </div>
    </main>
    <footer id="footer-menu" class="footer-menu landscape"></footer>
    <div id="modals"></div>
    <script type="text/javascript" src="../shared/js/vendor/jquery.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/veeva-library-4.2.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/ivaHelper-1.0.1.js"></script>
    <script type="text/javascript" src="../shared/js/foundation.min.js"></script>
    <script type="text/javascript" src="../shared/js/foundation/foundation.equalizer.js"></script>
    <script type="text/javascript" src="../shared/js/foundation/foundation.reveal.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/jquery.touchSwipe.min.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/iscroll.js"></script>
    <script type="text/javascript" src="../shared/js/global.js"></script>
    <script type="text/javascript" src="js/slide.js"></script>
  </body>
</html>